Cargando…
贝伐珠单抗在晚期非小细胞肺癌一线治疗中的研究进展
As the first anti-angiogenesis monoclonal antibody, bevacizumab has been an vital component of front line regimen of advanced nonsqaumous non-small cell lung cancer (NSCLC). It increase the efficacy of chemotherapy, epithelial growth factor receptor tyrosine kinase inhibitors and immune checkpoint i...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406442/ https://www.ncbi.nlm.nih.gov/pubmed/32702797 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.34 |